Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Key Documents

View All Documentation

P4498

Sigma-Aldrich

Pravastatin sodium salt hydrate

≥98% (HPLC), powder

Synonyme(s) :

(βR, δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-β, δ,6-trihydroxy-2-methyl-8[(2S)-2-methyl-1-oxobutoxyl]-1-naphthaleneheptanoic acid sodium hydrate, Eptastatin sodium salt hydrate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C23H35O7Na · xH2O
Numéro CAS:
81131-70-6
Poids moléculaire :
446.51 (anhydrous basis)
Numéro MDL:
MFCD00887601
Code UNSPSC :
12352200
ID de substance PubChem :
329820206
Nomenclature NACRES :
NA.77

Source biologique

synthetic (organic)

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

powder

Couleur

white

Pf

171.2-173 °C

Solubilité

H2O: >10 mg/mL

Auteur

Bristol-Myers Squibb

Température de stockage

2-8°C

Chaîne SMILES 

[Na+].[H][C@@](O)(CC[C@H]1[C@@H](C)C=CC2=C[C@@H](O)C[C@H](OC(=O)[C@@H](C)CC)[C@]12[H])C[C@@H](O)CC([O-])=O

InChI

1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1

Clé InChI

VWBQYTRBTXKKOG-IYNICTALSA-M

Informations sur le gène

human ... HMGCR(3156)

Description générale

Pravastatin sodium is an orally effective hypocholesterolaemic agent which is structurally similar to lovastatin and compactin.

Application

Pravastatin sodium salt hydrate has been used in the enzymatic method to measure mevalonic acid in serum.

Actions biochimiques/physiologiques

Pravastatin sodium is a competitive, water-soluble 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.
Competitive, water-soluble 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Inhibits cholesterol synthesis in vivo (Ki ~1 nM).

Caractéristiques et avantages

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, type N95 (US)

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Ashley J Bauer et al.
Hypertension (Dallas, Tex. : 1979), 61(5), 1103-1110 (2013-03-06)
Preeclampsia is a pregnancy-specific condition characterized by an imbalance of circulating angiogenic factors and new-onset hypertension. Although current treatment options are limited, recent studies suggest that pravastatin may improve angiogenic profile and reduce blood pressure in preeclampsia. We hypothesized pravastatin
Carlos S Kückelhaus et al.
Experimental parasitology, 134(1), 18-25 (2013-02-14)
The control of leishmaniases poses an important challenge due to the scarcity and toxicity of the pharmacological options available. We have previously shown that pravastatin significantly improves the course of the disease in Leishmania (L.) amazonensis-infected BALB/c mice. Since the
S M Singhvi et al.
British journal of clinical pharmacology, 29(2), 239-243 (1990-02-01)
Pravastatin sodium, a competitive inhibitor of HMG-CoA reductase, is a new orally effective hypocholesterolaemic agent. In a two-way crossover study, eight healthy male subjects each received an intravenous and an oral dose of [14C]-pravastatin sodium. The oral absorption of [14C]
Kevin F Erickson et al.
Journal of the American College of Cardiology, 61(12), 1250-1258 (2013-03-19)
The authors sought to evaluate the cost-effectiveness of statins for primary prevention of myocardial infarction (MI) and stroke in patients with chronic kidney disease (CKD). Patients with CKD have an elevated risk of MI and stroke. Although HMG Co-A reductase
Tsutomu Yamazaki et al.
International heart journal, 54(1), 33-39 (2013-02-23)
This paper describes a subanalysis of the JART Study comparing rosuvastatin and pravastatin treatment. A total of 314 subjects were analyzed in this subanalysis, 282 of whom were eligible for evaluation of the relationship between LDL-C and carotid mean-IMT change.
Afficher tous les articles scientifiques apparentés

Articles

Dietary Terpenes

Terpenes comprise the largest and most diverse class of secondary metabolites; approximately 55,000 compounds have been identified to date.

Cholesterol Biosynthesis Regulation

The amount of cholesterol that is synthesized in the liver is tightly regulated by dietary cholesterol levels. LDL receptors regulate the cellular transport of lipid rich low density lipoprotein (LDL) particles.

Antilipemic Agents

Antilipemic Agents

Antilipemic Agents

Randomized controlled clinical studies have suggested 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in both primary and secondary prevention of cardiovascular disease (CVD) events.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique